Application of Plackett–Burman Screening Design for Formulation of Telmisartan Nanosuspension

Abstract

Developing formulations for medications with low water solubility and low oral bioavailability presents significant challenges. Poor water solubility and a slow rate of dissolution are issues for the majority of newly developed and well-established biologically active compounds. Telmisartan (TM) is a BCS class-II medication characterized by low solubility as well as high permeability. The current study set out to determine crucial formulation and processing characteristics that could affect the nanosuspension's quality. Using the nanoprecipitation- ultrasonication process, a poorly soluble medication was converted into a nanosuspension formulation. In order to screen five independent factors—the amount of stabilizer (mg) (X2), the amount of Telmisartan (mg) (X1), the volume ratio of solvent to anti-solvent (X3), the speed.  of stirring (RPM) (X4), and the sonication time (min) (X5)—a total of eight experiments were created. The dependent factors used were saturation solubility (μg/ml) and mean particle size (nm). The acquired results demonstrated that, in comparison to all other stabilizers, the nanosuspension made with Poloxamer 407 has improved saturation solubility. The amount of telmisartan and the speed at which the mixture is stirred were also discovered to be potential formulation and processing parameters that exert considerable influence on the quality of the telmisartan nanosuspension.